Next Article in Journal
Exploring Patient Awareness and Perceptions of the Appropriate Use of Antibiotics: A Mixed-Methods Study
Previous Article in Journal
Antibiotic Prescribing for Uncomplicated Acute Bronchitis Is Highest in Younger Adults
Article Menu

Export Article

Open AccessReview
Antibiotics 2017, 6(4), 24;

Fosfomycin: Pharmacological, Clinical and Future Perspectives

Centre for Human Drug Research, Leiden, 2333 CL, The Netherlands
Department of Medical Microbiology, Albert Schweitzer Hospital, Dordrecht, 3318 AT, The Netherlands
Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, 6500 HB, The Netherlands
Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, 3015 CN, The Netherlands
Hospital Pharmacy, The Hague Hospitals, The Hague, 2545 AB, The Netherlands
Department of Internal Medicine, Haga Teaching Hospital, The Hague, 2566 MJ, The Netherlands
Groningen Research Institute for Asthma and COPD, Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, 9713 GZ, The Netherlands
Author to whom correspondence should be addressed.
Academic Editor: Christopher C. Butler
Received: 30 May 2017 / Revised: 18 October 2017 / Accepted: 19 October 2017 / Published: 31 October 2017
Full-Text   |   PDF [1187 KB, uploaded 1 November 2017]   |  


Fosfomycin is a bactericidal, low-molecular weight, broad-spectrum antibiotic, with putative activity against several bacteria, including multidrug-resistant Gram-negative bacteria, by irreversibly inhibiting an early stage in cell wall synthesis. Evidence suggests that fosfomycin has a synergistic effect when used in combination with other antimicrobial agents that act via a different mechanism of action, thereby allowing for reduced dosages and lower toxicity. Fosfomycin does not bind to plasma proteins and is cleared via the kidneys. Due to its extensive tissue penetration, fosfomycin may be indicated for infections of the CNS, soft tissues, bone, lungs, and abscesses. The oral bioavailability of fosfomycin tromethamine is <50%; therefore, oral administration of fosfomycin tromethamine is approved only as a 3-gram one-time dose for treating urinary tract infections. However, based on published PK parameters, PK/PD simulations have been performed for several multiple-dose regimens, which might lead to the future use of fosfomycin for treating complicated infections with multidrug-resistant bacteria. Because essential pharmacological information and knowledge regarding mechanisms of resistance are currently limited and/or controversial, further studies are urgently needed, and fosfomycin monotherapy should be avoided. View Full-Text
Keywords: fosfomycin; pharmacokinetics; multidrug resistance; antimicrobial activity fosfomycin; pharmacokinetics; multidrug resistance; antimicrobial activity

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Dijkmans, A.C.; Zacarías, N.V.O.; Burggraaf, J.; Mouton, J.W.; Wilms, E.B.; van Nieuwkoop, C.; Touw, D.J.; Stevens, J.; Kamerling, I.M.C. Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics 2017, 6, 24.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Antibiotics EISSN 2079-6382 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top